143 related articles for article (PubMed ID: 38677720)
1. Safety and tolerability of OP-724 in patients with haemophilia and liver cirrhosis due to HIV/HCV coinfection: an investigator-initiated, open-label, non-randomised, single-centre, phase I study.
Kimura K; Tanuma J; Kimura M; Imamura J; Yanase M; Ieiri I; Kurosaki M; Watanabe T; Endo T; Yotsuyanagi H; Gatanaga H
BMJ Open Gastroenterol; 2024 Apr; 11(1):. PubMed ID: 38677720
[TBL] [Abstract][Full Text] [Related]
2. Safety, tolerability, and anti-fibrotic efficacy of the CBP/β-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study.
Kimura K; Kanto T; Shimoda S; Harada K; Kimura M; Nishikawa K; Imamura J; Ogawa E; Saio M; Ikura Y; Okusaka T; Inoue K; Ishikawa T; Ieiri I; Kishimoto J; Todaka K; Kamisawa T
EBioMedicine; 2022 Jun; 80():104069. PubMed ID: 35605429
[TBL] [Abstract][Full Text] [Related]
3. Feasibility, safety and tolerability of the CREB-binding protein/β-catenin inhibitor OP-724 in patients with advanced primary biliary cholangitis: an investigator-initiated, open-label, non-randomised, two-centre, phase 1 study.
Kimura M; Ogawa E; Harada K; Imamura J; Saio M; Ikura Y; Yatsuhashi H; Murata K; Miura K; Ieiri I; Tanaka A; Kimura K
BMJ Open Gastroenterol; 2022 Nov; 9(1):. PubMed ID: 36442892
[TBL] [Abstract][Full Text] [Related]
4. Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/β-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial.
Kimura K; Ikoma A; Shibakawa M; Shimoda S; Harada K; Saio M; Imamura J; Osawa Y; Kimura M; Nishikawa K; Okusaka T; Morita S; Inoue K; Kanto T; Todaka K; Nakanishi Y; Kohara M; Mizokami M
EBioMedicine; 2017 Sep; 23():79-87. PubMed ID: 28844410
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.
Rockstroh JK; Nelson M; Katlama C; Lalezari J; Mallolas J; Bloch M; Matthews GV; Saag MS; Zamor PJ; Orkin C; Gress J; Klopfer S; Shaughnessy M; Wahl J; Nguyen BY; Barr E; Platt HL; Robertson MN; Sulkowski M
Lancet HIV; 2015 Aug; 2(8):e319-27. PubMed ID: 26423374
[TBL] [Abstract][Full Text] [Related]
6. Liver stiffness and aspartate aminotransferase levels predict the risk for liver fibrosis progression in hepatitis C virus/HIV-coinfected patients.
Gonzalez FA; Van den Eynde E; Perez-Hoyos S; Navarro J; Curran A; Burgos J; Falcó V; Ocaña I; Ribera E; Crespo M
HIV Med; 2015 Apr; 16(4):211-8. PubMed ID: 25234826
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial.
Andrieux-Meyer I; Tan SS; Thanprasertsuk S; Salvadori N; Menétrey C; Simon F; Cressey TR; Said HRHM; Hassan MRA; Omar H; Tee HP; Chan WK; Kumar S; Thongsawat S; Thetket K; Avihingsanon A; Khemnark S; Yerly S; Ngo-Giang-Huong N; Siva S; Swanson A; Goyal V; Bompart F; Pécoul B; Murad S
Lancet Gastroenterol Hepatol; 2021 Jun; 6(6):448-458. PubMed ID: 33865507
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic performance of APRI and FIB-4 for confirming cirrhosis in Indonesian HIV/HCV co-infected patients.
Yunihastuti E; Wicaksana B; Wiraguna A; Hidayah AJ; Amelia F; Natali V; Widhani A; Sulaiman AS; Kurniawan J
BMC Infect Dis; 2020 May; 20(1):372. PubMed ID: 32450844
[TBL] [Abstract][Full Text] [Related]
9. Impact of Antiretroviral Therapy on Liver Fibrosis Among Human Immunodeficiency Virus-Infected Adults With and Without HBV Coinfection in Zambia.
Vinikoor MJ; Sinkala E; Chilengi R; Mulenga LB; Chi BH; Zyambo Z; Hoffmann CJ; Saag MS; Davies MA; Egger M; Wandeler G;
Clin Infect Dis; 2017 May; 64(10):1343-1349. PubMed ID: 28158504
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.
Sulkowski M; Hezode C; Gerstoft J; Vierling JM; Mallolas J; Pol S; Kugelmas M; Murillo A; Weis N; Nahass R; Shibolet O; Serfaty L; Bourliere M; DeJesus E; Zuckerman E; Dutko F; Shaughnessy M; Hwang P; Howe AY; Wahl J; Robertson M; Barr E; Haber B
Lancet; 2015 Mar; 385(9973):1087-97. PubMed ID: 25467560
[TBL] [Abstract][Full Text] [Related]
11. Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disorders.
Uemura H; Tsukada K; Mizushima D; Aoki T; Watanabe K; Kinai E; Teruya K; Gatanaga H; Kikuchi Y; Sugiyama M; Mizokami M; Oka S
PLoS One; 2017; 12(10):e0186255. PubMed ID: 29045448
[TBL] [Abstract][Full Text] [Related]
12. Correlation of transient elastography with APRI and FIB-4 in a cohort of patients with congenital bleeding disorders and HCV or HIV/HCV coinfection.
Vidovic N; Lochowsky RS; Goldmann G; Rockstroh J; Wasmuth JC; Spengler U; Sauerbruch T; Lammert F; Oldenburg J; Grünhage F
Haemophilia; 2010 Sep; 16(5):778-85. PubMed ID: 20331759
[TBL] [Abstract][Full Text] [Related]
13. Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial.
Doyle MA; Singer J; Lee T; Muir M; Cooper C
Trials; 2016 Jul; 17(1):331. PubMed ID: 27439433
[TBL] [Abstract][Full Text] [Related]
14. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
Molina JM; Orkin C; Iser DM; Zamora FX; Nelson M; Stephan C; Massetto B; Gaggar A; Ni L; Svarovskaia E; Brainard D; Subramanian GM; McHutchison JG; Puoti M; Rockstroh JK;
Lancet; 2015 Mar; 385(9973):1098-106. PubMed ID: 25659285
[TBL] [Abstract][Full Text] [Related]
15. Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort.
Quaranta MG; Ferrigno L; Tata X; D'Angelo F; Coppola C; Ciancio A; Bruno SR; Loi M; Giorgini A; Margotti M; Cossiga V; Brancaccio G; Dallio M; De Siena M; Cannizzaro M; Cavalletto L; Massari M; Mazzitelli M; De Leo P; Laccabue D; Baiocchi L; Kondili LA
BMC Infect Dis; 2021 May; 21(1):413. PubMed ID: 33947337
[TBL] [Abstract][Full Text] [Related]
16. The Impact of Markers of HIV Infection on Change in Liver Stiffness in People With HIV and Hepatitis C Virus Co-infection After Treatment and Cure of Hepatitis C.
van Santen DK; Agius PA; Sasadeusz J; Fairley CK; Sievert W; Gane E; Iser D; O'Reilly M; Medland NA; Moore R; Hellard ME; Hoy JF; Doyle JS;
J Acquir Immune Defic Syndr; 2020 Dec; 85(5):e81-e89. PubMed ID: 32842055
[TBL] [Abstract][Full Text] [Related]
17. Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration.
Castera L; Winnock M; Pambrun E; Paradis V; Perez P; Loko MA; Asselineau J; Dabis F; Degos F; Salmon D
HIV Med; 2014 Jan; 15(1):30-9. PubMed ID: 24007567
[TBL] [Abstract][Full Text] [Related]
18. Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial.
Rockstroh JK; Bhagani S; Hyland RH; Yun C; Dvory-Sobol H; Zheng W; Brainard DM; Ingiliz P; Lutz T; Boesecke C; Nelson M
Lancet Gastroenterol Hepatol; 2017 May; 2(5):347-353. PubMed ID: 28397698
[TBL] [Abstract][Full Text] [Related]
19. High Proportion of HIV-HCV Coinfected Patients with Advanced Liver Fibrosis Requiring Hepatitis C Treatment in Haiphong, Northern Vietnam (ANRS 12262).
Nguyen Truong T; Laureillard D; Lacombe K; Duong Thi H; Pham Thi Hanh P; Truong Thi Xuan L; Chu Thi N; Luong Que A; Vu Hai V; Nagot N; Tuaillon E; Dominguez S; Lemoine M
PLoS One; 2016; 11(5):e0153744. PubMed ID: 27148964
[TBL] [Abstract][Full Text] [Related]
20. Prediction of liver stiffness by serum indexes in HCV-infected patients with or without HIV coinfection.
Merchante N; Mena Á; Pascasio JM; Marco A; Rodriguez M; Hernandez-Guerra M; Simón MA
Medicine (Baltimore); 2021 Nov; 100(46):e27838. PubMed ID: 34797315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
